This session will review novel pharmacological agents and mechanisms of action recently approved or in late-stage development for schizophrenia. Learners will gain insights into efficacy, safety, and tolerability data, as well as practical considerations for incorporating these latest and evidence-based therapies into individualized treatment plans.